Healthcare provider profile · identity verified

Carlos Eugenio Carrion, M.D.

General Practice · HUMACAO, PR · NPI 1346277407

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	635	225
Lisinopril	Lisinopril	351	117
Amlodipine Besylate	Amlodipine Besylate	340	111
Gabapentin	Gabapentin	327	96
Losartan Potassium	Losartan Potassium	291	100
Simvastatin	Simvastatin	259	84
Metformin Hcl	Metformin Hcl	246	78
Levothyroxine Sodium	Levothyroxine Sodium	235	71
Omeprazole	Omeprazole	225	84
Famotidine	Famotidine	212	76
Hydrochlorothiazide	Hydrochlorothiazide	177	61
Tamsulosin Hcl	Tamsulosin Hcl	165	55
Glipizide	Glipizide	162	52
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	130	82
Montelukast Sodium	Montelukast Sodium	122	55
Clopidogrel	Clopidogrel Bisulfate	105	36
Metoprolol Succinate	Metoprolol Succinate	102	40
Metoprolol Tartrate	Metoprolol Tartrate	100	34
Synthroid	Levothyroxine Sodium	95	30
Clonazepam	Clonazepam	93	22
Alendronate Sodium	Alendronate Sodium	87	28
Trijardy Xr	Empaglifloz/Linaglip/Metformin	87	29
Diclofenac Sodium	Diclofenac Sodium	82	49
Furosemide	Furosemide	77	28
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	70	43
Tizanidine Hcl	Tizanidine Hcl	64	46
Donepezil Hcl	Donepezil Hcl	63	25
Fenofibrate	Fenofibrate	63	34
Finasteride	Finasteride	60	22
Sertraline Hcl	Sertraline Hcl	60	22
Carvedilol	Carvedilol	58	21
Naproxen	Naproxen	57	36
Trazodone Hcl	Trazodone Hcl	57	24
Atenolol	Atenolol	56	21
Tramadol Hcl	Tramadol Hcl	55	17
Doxazosin Mesylate	Doxazosin Mesylate	51	15
Meloxicam	Meloxicam	50	28
Rosuvastatin Calcium	Rosuvastatin Calcium	49	22
Albuterol Sulfate Hfa	Albuterol Sulfate	48	22
Irbesartan	Irbesartan	44	12
Pantoprazole Sodium	Pantoprazole Sodium	43	17
Buspirone Hcl	Buspirone Hcl	42	14
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	42	15
Lantus	Insulin Glargine,hum.Rec.Anlog	41	suppressed
Lorazepam	Lorazepam	41	suppressed
Fluticasone Propionate	Fluticasone Propionate	39	18
Nifedipine Er	Nifedipine	38	12
Temazepam	Temazepam	38	suppressed
Moxifloxacin Hcl	Moxifloxacin Hcl	37	34
Spironolactone	Spironolactone	35	13
Latanoprost	Latanoprost	34	15
Verapamil Er	Verapamil Hcl	34	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	33	33
Glyxambi	Empagliflozin/Linagliptin	33	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	30	suppressed
Meclizine Hcl	Meclizine Hcl	30	18
Xarelto	Rivaroxaban	30	11
Eliquis	Apixaban	29	12
Pioglitazone Hcl	Pioglitazone Hcl	29	11
Lovastatin	Lovastatin	28	suppressed
Betamethasone Valerate	Betamethasone Valerate	27	20
Glipizide Er	Glipizide	26	suppressed
Ibandronate Sodium	Ibandronate Sodium	24	suppressed
Nabumetone	Nabumetone	24	13
Novolin N	Insulin Nph Human Isophane	24	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	24	18
Enalapril Maleate	Enalapril Maleate	23	suppressed
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	23	suppressed
Levofloxacin	Levofloxacin	23	23
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	23	suppressed
Clonidine Hcl	Clonidine Hcl	22	suppressed
Hydralazine Hcl	Hydralazine Hcl	22	suppressed
Pentoxifylline	Pentoxifylline	21	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	20	11
Fluoxetine Hcl	Fluoxetine Hcl	19	suppressed
Glimepiride	Glimepiride	19	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	19	suppressed
Pregabalin	Pregabalin	19	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	18	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	18	suppressed
Raloxifene Hcl	Raloxifene Hcl	18	suppressed
Trulicity	Dulaglutide	18	suppressed
Baclofen	Baclofen	17	11
Ketorolac Tromethamine	Ketorolac Tromethamine	17	12
Lansoprazole	Lansoprazole	17	suppressed
Alprazolam	Alprazolam	16	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	16	suppressed
Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	16	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	16	suppressed
Azithromycin	Azithromycin	15	14
Bicalutamide	Bicalutamide	15	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	15	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	15	suppressed
Breo Ellipta	Fluticasone/Vilanterol	14	suppressed
Synjardy	Empagliflozin/Metformin Hcl	14	suppressed
Warfarin Sodium	Warfarin Sodium	14	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	13	suppressed
Fluconazole	Fluconazole	13	13
Linzess	Linaclotide	13	suppressed
Mupirocin	Mupirocin	13	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	13	suppressed
Clobetasol Propionate	Clobetasol Propionate	12	suppressed
Ezetimibe	Ezetimibe	12	suppressed
Glycopyrrolate	Glycopyrrolate	12	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	12	suppressed
Methotrexate	Methotrexate Sodium	12	suppressed
Methylprednisolone	Methylprednisolone	12	suppressed
Phenobarbital	Phenobarbital	12	suppressed
Toujeo Max Solostar	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	12	suppressed
Allopurinol	Allopurinol	11	suppressed
Candesartan Cilexetil	Candesartan Cilexetil	11	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	11	suppressed
Cilostazol	Cilostazol	11	suppressed
Duloxetine Hcl	Duloxetine Hcl	11	suppressed
Novolog	Insulin Aspart	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error